免疫检查点抑制剂治疗中免疫相关不良反应的临床表现及处理

发布时间：2018-03-30 05:29

本文选题：检查点　切入点：黑色素瘤　出处：《中国免疫学杂志》2017年04期

【摘要】：正免疫检查点阻断治疗是当今备受瞩目的新兴肿瘤治疗方式。不同于以往其他治疗方式,免疫检查点抑制剂靶向机体免疫系统而非肿瘤细胞,旨在恢复并促进效应T细胞特异性识别和杀伤肿瘤细胞的功能,系统性增强全身的抗肿瘤免疫反应,因而代表了当前肿瘤治疗模式的转变。迄今多个临床试验已证实免疫检查点抑制剂在晚期黑色素瘤、非小细胞肺癌(Non-small-cell lung cancer,NSCLC)及膀胱
[Abstract]:The positive immunological checkpoint blocking therapy is one of the most popular methods for the treatment of neoplasms. Unlike other treatments, immunocheckpoint inhibitors target the body's immune system rather than tumor cells. The aim is to restore and promote the function of specific recognition and killing of tumor cells by effector T cells, and to systematically enhance the anti-tumor immune response of the whole body. So far, a number of clinical trials have confirmed immunological checkpoint inhibitors in advanced melanoma, non-small- cell lung cancer-NSCLC) and bladder.
【作者单位】：上海交通大学医学院附属仁济医院妇产科上海市妇科肿瘤重点实验室;
【基金】：国家自然科学基金面上项目(81472843) 上海市科学技术委员会上海市科研计划项目(14ZR1424700)资助
【分类号】：R730.51

【相似文献】